US FDA warning letter at Indore facility
Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.
CIPLA / Q3-FY24 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Goa facility re-inspection uncertainty
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
US generic pricing compression
Pricing environment in US generics is in a downcycle; compression expected to move from 4-6% to 6-8% within a year.
Abraxane launch delay
Abraxane launch via third-party transfer is taking longer; fastest route is from Goa facility, which is subject to FDA inspection.